Literature DB >> 1897529

High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.

A Zimran1, T Gelbart, B Westwood, G A Grabowski, E Beutler.   

Abstract

Reliable estimates of the frequency of Gaucher disease-producing mutations are not available. The high frequency of Gaucher disease in the Ashkenazi Jewish population is due to the occurrence of a mutation at nucleotide (nt) 1226. We have screened 593 DNA samples from normal Ashkenazi Jews, as well as 62 DNA samples from all our Ashkenazi Jewish patients with Gaucher disease, for the presence of the 1226 mutation. In the 593 presumed normal Ashkenazi Jewish individuals the 1226 mutation was identified in the heterozygous state in 37 and in the homozygous state in two, giving a gene frequency of .035 for the mutation. This 1226 mutation represented 73% of the 124 Gaucher disease alleles in Jewish Gaucher disease patients. Accordingly we estimate that the gene frequency for Gaucher disease among the Ashkenazi Jewish population is .047, which is equivalent to a carrier frequency of 8.9% and a birth incidence of 1:450.

Entities:  

Mesh:

Year:  1991        PMID: 1897529      PMCID: PMC1683177     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  14 in total

1.  Gaucher's disease without splenomegaly. Oldest patient on record, with review.

Authors:  L BRINN; S GLABMAN
Journal:  N Y State J Med       Date:  1962-07-15

2.  Misuse of marrow examination in the diagnosis of Gaucher disease.

Authors:  E Beutler; A Saven
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113

3.  The facile detection of the nt 1226 mutation of glucocerebrosidase by 'mismatched' PCR.

Authors:  E Beutler; T Gelbart; C West
Journal:  Clin Chim Acta       Date:  1990-12-24       Impact factor: 3.786

4.  Designed diagnostic restriction fragment length polymorphisms for the detection of point mutations in ras oncogenes.

Authors:  R Kumar; L L Dunn
Journal:  Oncogene Res       Date:  1989

5.  Detection of the 1226 (Jewish) mutation for Gaucher's disease by color PCR. A means for studying the gene frequency of the disorder.

Authors:  A Zimran; W C Kuhl; E Beutler
Journal:  Am J Clin Pathol       Date:  1990-06       Impact factor: 2.493

6.  Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals.

Authors:  S Tsuji; B M Martin; J A Barranger; B K Stubblefield; M E LaMarca; E I Ginns
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

7.  An improved method for prenatal diagnosis of genetic diseases by analysis of amplified DNA sequences. Application to hemophilia A.

Authors:  S C Kogan; M Doherty; J Gitschier
Journal:  N Engl J Med       Date:  1987-10-15       Impact factor: 91.245

8.  Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA.

Authors:  J Sorge; C West; B Westwood; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  Gaucher disease: molecular heterogeneity and phenotype-genotype correlations.

Authors:  B Theophilus; T Latham; G A Grabowski; F I Smith
Journal:  Am J Hum Genet       Date:  1989-08       Impact factor: 11.025

10.  Prediction of severity of Gaucher's disease by identification of mutations at DNA level.

Authors:  A Zimran; J Sorge; E Gross; M Kubitz; C West; E Beutler
Journal:  Lancet       Date:  1989-08-12       Impact factor: 79.321

View more
  39 in total

1.  Mutation analysis in 46 British and Irish patients with Gaucher's disease.

Authors:  C E Hatton; A Cooper; C Whitehouse; J E Wraith
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

Review 2.  Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.

Authors:  Marianne Rohrbach; Joe T R Clarke
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.

Authors:  J J MacKenzie; D Amato; J T Clarke
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

4.  Overexpression of human glucocerebrosidase containing different-sized leaders.

Authors:  M Pasmanik-Chor; O Elroy-Stein; H Aerts; V Agmon; S Gatt; M Horowitz
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

5.  Demographic Studies from a National Gaucher Disease Screening Program.

Authors:  D M Gagnon; E Pergament; B A Fine
Journal:  J Genet Couns       Date:  1998-10       Impact factor: 2.537

Review 6.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

7.  Intracellular degradation of fluorescent glycolipids by lysosomal enzymes and their activators.

Authors:  L Madar-Shapiro; M Pasmanik-Chor; T Dinur; A Dagan; S Gatt; M Horowitz
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

8.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.

Authors:  Juliane Neumann; Jose Bras; Emma Deas; Sean S O'Sullivan; Laura Parkkinen; Robin H Lachmann; Abi Li; Janice Holton; Rita Guerreiro; Reema Paudel; Badmavady Segarane; Andrew Singleton; Andrew Lees; John Hardy; Henry Houlden; Tamas Revesz; Nicholas W Wood
Journal:  Brain       Date:  2009-03-13       Impact factor: 13.501

9.  Phenotypic and genotypic heterogeneity in gaucher disease: Implications for genetic counseling.

Authors:  E Sidransky; E I Ginns
Journal:  J Genet Couns       Date:  1994-03       Impact factor: 2.537

10.  Gaucher disease: gene frequencies in the Ashkenazi Jewish population.

Authors:  E Beutler; N J Nguyen; M W Henneberger; J M Smolec; R A McPherson; C West; T Gelbart
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.